Epinephrine for anaphylaxis: Underutilized and unavailable

Western Journal of Emergency Medicine

Volumn 16, Issue 3, 2015, Pages 1-3

  Dudley, Larissa S ^a   Mansour, Madonna I ^b   Merlin, Mark A ^c  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Allergic Reactions; Anaphylaxis; Epinephrine

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; EPINEPHRINE;

ANAPHYLAXIS; AUTOINJECTOR; HEALTH CARE AVAILABILITY; HEALTH CARE PRACTICE; HUMAN; REVIEW; THERAPY DELAY; COMMUNITY MEDICINE; FIRST AID; INTRAMUSCULAR DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; SCHOOL; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADRENERGIC AGONISTS; ANAPHYLAXIS; COMMUNITY MEDICINE; EPINEPHRINE; FIRST AID; HUMANS; INJECTIONS, INTRAMUSCULAR; SCHOOLS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84929082632     PISSN: 1936900X     EISSN: 19369018     Source Type: Journal    
DOI: 10.5811/westjem.2015.3.25337     Document Type: Review

References (21)

1. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol. 2004;4:285-90.
2. Kemp SF, Lockey RF, Simons FE. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy. 2008;63:1061-1070.
3. Liberman P, Camargo JR, Bohlke K, et al. Epidemiology of anaphylaxis: fndings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97(5):596-602.
4. Moneret-Vautrin DA, Morisset M, Flabbee J, et al. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy. 2005;60:443-51.
5. NIAID-Sponsored Expert Panel, Boyce JA, Burks AW. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel. J Allergy Clin Immunol. 2010;126:S11-S12.
6. Ma L, Danoff T, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(4):1075-1083.
7. Wood R, Camargo C, Lieberman P, et al. Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 133(2):461-467.
8. DeSantiago-Cardenas L, Rivkina V, Whyte S, et al. Emergency epinephrine use for food allergy reactions in chicago public schools. Am J Prev Med. 2015;48(2):170-173.
9. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the defnition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-7.
10. Simons FE, Ardusso LRF, Dimov V, et al. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunology. 2013;162:193-204.
11. Ross MP, Ferguson M, Street D, et al. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol. 2008;121:166-171.
12. Ben-Shoshan M, Kagan R, Primeau MN, et al. Availability of the epinephrine auto injector at school in children with peanut allergy. Ann Allergy Asthma Immunol. 2008;100(6):570-575.
13. Ercan H, Ozen A, Karatepe H, et al. Primary school teachers' knowledge about and attitudes toward anaphylaxis. Pediatr Allergy Immunol. 2012;23:428-432.
14. Jacobsen RC, Toy S, Bonham AJ, et al. Anaphylaxis knowledge among paramedics: results of a national survey. Prehosp Emerg Care. 2012;16:527-534.
15. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005;95:217-26.
16. Simmons F, Clark S, Camargo C. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol. 2009;124:301-306.
17. Manivannan V, Hyde RJ, Hankins DG, et al. Epinephrine use and outcomes in anaphylaxis patients transported by emergency medical services. Am J Emerg Med. 2014;32:1097-1102.
18. Berger S. Cardiopulmonary resuscitation and public access defbrillation in the current era-can we do better yet? J Am Heart Assoc. 2014;3(2):e000945.
19. Murakami Y, Iwami T, Kitamura T, et al. Outcomes of out-of-hospital cardiac arrest by public location in the public-access defbrillation era. J Am Heart Assoc. 2014;3(2):e000533.
20. BioRidge Pharma. EpiPen (epinepherine) auto-injectors epipen4schools program. http://www.bioridgepharma.com/programs. html.
21. Muck A, Bebarta V, Borys D, et al. Six years of epinephrine digital injections: absence of signifcant local or systemic effects. Ann Emerg Med. 2010;56(3):270-4.